Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a29cae525d2ceefa

Jump to content

Etamivan

From Wikipedia, the free encyclopedia
(Redirected from Ethamivan)

Etamivan
Clinical data
Trade namesAnalepticon
ATC code
Identifiers
  • N,N-Diethyl-4-hydroxy-3-methoxybenzamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.005.599 Edit this at Wikidata
Chemical and physical data
FormulaC12H17NO3
Molar mass223.272 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)c1ccc(O)c(OC)c1
  • InChI=1S/C12H17NO3/c1-4-13(5-2)12(15)9-6-7-10(14)11(8-9)16-3/h6-8,14H,4-5H2,1-3H3 X markN
  • Key:BQJODPIMMWWMFC-UHFFFAOYSA-N X markN
 X markNcheckY (what is this?)  (verify)

Etamivan (INN, or ethamivan (USAN); trade names Analepticon, Emivan, and Vandid) is a respiratory stimulant drug[1] related to nikethamide. It was mainly used in the treatment of barbiturate overdose[2] and chronic obstructive pulmonary disease,[3] but has now largely fallen into disuse.

Adverse effects which are common to the respiratory stimulant class include sneezing, coughing, and laryngospasm when infused too rapidly. More serious adverse events include muscle twitching, tremors, and convulsions. The dose to treat barbiturate intoxication or carbon dioxide narcosis in adults ranges from 0.5 mg/kg to 5.0 mg/kg, infused intravenously over several minutes. Epilepsy and the use of monoamine oxidase inhibitors or other adrenergic drugs are contraindications.[4]

References

[edit]
  1. Hirsh K, Wang SC (May 1975). "Respiratory stimulant effects of ethamivan and picrotoxin". The Journal of Pharmacology and Experimental Therapeutics. 193 (2): 657–63. PMID 1173598.
  2. Wheeldon PJ, Perry AW (July 1963). "The use of ethamivan in the treatment of barbiturate poisoning". Canadian Medical Association Journal. 89 (1): 20–2. PMC 1921664. PMID 14000228.
  3. Sproule BJ, Jans RL, Breitkreutz H, Mahon W (December 1964). "Effects of ethamivan in patients with chronic respiratory disease". Canadian Medical Association Journal. 91 (23): 1203–8. PMC 1928498. PMID 14226094.
  4. American Medical Association Dept of Drugs (1977). AMA Drug Evaluations (3rd ed.). Littleton, Mass.: Pub. Sciences Group. p. N-61. ISBN 978-0-88416-175-2. OCLC 1024170745.